Cancer patients with breast cancer or exposed to the ADR-CYP regimen were not found with different DNM1 levels compared to other cancer patients (P ​> ​0.05, data not reported), suggesting that a rodent model for breast cancer and ADR-CYP exposure is possibly representative of this AYA cohort with regards our investigation into DNM1 activity in the hippocampus. This evidence concerns the gene DNM1 and breast cancer.